2013
Studies of NVP-BEZ235 in melanoma.
Sznol JA, Jilaveanu LB, Kluger HM. Studies of NVP-BEZ235 in melanoma. Current Cancer Drug Targets 2013, 13: 165-74. PMID: 23215722, DOI: 10.2174/1568009611313020006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsClinical Trials as TopicHumansImidazolesMelanomaPhosphoinositide-3 Kinase InhibitorsQuinolinesTOR Serine-Threonine KinasesConceptsNVP-BEZ235Dual PI3K/mTOR inhibitorNovel dual PI3K/mTOR inhibitorPI3K/mTOR inhibitorSpecific molecular inhibitorsPotential escape mechanismsMTOR inhibitorsPI3K-pathwayEscape mechanismsMulti-level targetingMalignant melanocytesMolecular inhibitorsDrug developmentMelanomaAttractive targetInhibitorsPathwayNumerous studies
2011
In vitro studies of dasatinib, its targets and predictors of sensitivity
Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell & Melanoma Research 2011, 24: 386-389. PMID: 21320292, PMCID: PMC4431976, DOI: 10.1111/j.1755-148x.2011.00835.x.Peer-Reviewed Original Research